When was Satsuma Pharmaceuticals founded?

Satsuma Pharmaceuticals was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Satsuma Pharmaceuticals located?

Satsuma Pharmaceuticals is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

Who is the current CEO of Satsuma Pharmaceuticals?

Ryoichi Nagata of Satsuma Pharmaceuticals.

How many employees does Satsuma Pharmaceuticals have?

As of Sep 30, 2026, the latest employee count at Satsuma Pharmaceuticals is 28.

Is Satsuma Pharmaceuticals a funded company?

Satsuma Pharmaceuticals is a funded company, having raised a total of $74.1M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 05, 2017.

How much is Satsuma Pharmaceuticals worth?

The last known valuation of Satsuma Pharmaceuticals was $***** as of Sep 06, 2019.

When was the latest funding round of Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' latest funding was a $***** Post IPO round on Mar 01, 2021, with participation from 8 investors.

Where does Satsuma Pharmaceuticals rank among its competitors?

Satsuma Pharmaceuticals ranks 2nd amongst 4 active competitors, only 1 of which is funded. Vedana Therapeutics, which secured $46M in Jun, 2026.

Who are the top competitors of Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' top competitors include Vedana Therapeutics, Stopain Clinical and DMR BIOLOGICS. Among them, Vedana Therapeutics secured the most recent funding round in June, 2026.

Satsuma Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Satsuma Pharmaceuticals is an acquired company based in San Francisco (United States), founded in 2016. It operates as a Developer of therapeutics for migraine sufferers. Satsuma Pharmaceuticals has raised $74.1M in funding from investors like TPG, RA Capital Management and Wellington, with last known valuation of $*****. The company has 4 active competitors, including 1 funded and 1 that has exited. Its top competitors include companies like Vedana Therapeutics, Stopain Clinical and DMR BIOLOGICS.

Company Details

Developer of therapeutics for migraine sufferers. The company's lead product is STS101, for the acute treatment of migraine with a proprietary nasal powder formulation and dihydroergotamine mesylate (DHE), administered via the proprietary nasal delivery device.

Website: www.satsumarx.com/
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2016

Location

San Francisco, United States

Stage

Acquired

Total Funding

$74.1M in 3 rounds

Latest Funding Round

Post IPO, Mar 01, 2021, $*****

Last Known Valuation

$***** as on Sep 06, 2019

Investors

TPG & 17 more

Ranked

2^nd among 4 active competitors

Employee Count

28 as on Sep 30, 2026

Similar Companies

Vedana Therapeutics & 3 more

Exit Details

Acquired by Shin Nippon Biomedical Laboratories (Apr 16, 2023)

View Satsuma Pharmaceuticals' full profile

Satsuma Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Satsuma Pharmaceuticals, Inc. CIN: 813039831 , United States, Active	Dec 26, 999	-	13 (As on Dec 31, 2024)	-

Satsuma Pharmaceuticals got acquired by Shin Nippon Biomedical Laboratories on Apr 16, 2023 at an acquisition amount of $*****.

Click here to take a look at Satsuma Pharmaceuticals's acquisition in detail

Satsuma Pharmaceuticals has raised a total funding of $74.1M over 3 rounds. Its first funding round was on Jan 05, 2017. Its latest funding round was a Post IPO round on Mar 01, 2021 for $*****. 8 investors participated in its latest round. Satsuma Pharmaceuticals has 18 institutional investors.

Here is the list of recent funding rounds of Satsuma Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2021	8343568	Post IPO	6138230	9008308	8006409	9570670
Apr 24, 2019	6091614	Series B	4770906	4164949	2906154	TPG & 9 more
Jan 05, 2017	2094506	Series A	1073405	8059431	RA Capital Management & 2 more	5414686

Access funding benchmarks and valuations. Sign up today!

View details of Satsuma Pharmaceuticals's funding rounds and investors

Satsuma Pharmaceuticals' employee count trend

Satsuma Pharmaceuticals has 28 employees as of Sep 26. Here is Satsuma Pharmaceuticals's employee count trend over the years:

Employee count trend for Satsuma Pharmaceuticals

Uncover Satsuma Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Satsuma Pharmaceuticals include Vedana Therapeutics, Stopain Clinical and DMR BIOLOGICS. Here is the list of Top 10 competitors of Satsuma Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Vedana Therapeutics 2024, Seattle (United States), Series A	Developer of novel biologics targeting pathways for chronic migraine prevention	$46M	Canaan, Westlake Village Biopartners & 2 others	50/100
2nd	Satsuma Pharmaceuticals 2016, San Francisco (United States), Acquired	Developer of therapeutics for migraine sufferers	$74.1M	Point72, RA Capital Management & 16 others	47/100
3rd	Stopain Clinical 2016, Hazleton (United States), Funding Raised	Developer of drugs for treating migraine pain	-	-	25/100
4th	DMR BIOLOGICS 2016, Schofield (United States), Deadpooled	Provider of drugs for migraine pain management	-	-	18/100
5th	TrioxBio 2015, Ramat Gan (Israel), Funding Raised	Developing nitric oxide-inhibiting drugs for migraine disorders	-	venture CAPITAL funding	13/100